logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

WCLC 2019 – Durvalumab plus chemotherapy significantly improves survival in patients with extensive-stage SCLC

According to the CASPIAN study, adding immunotherapy to the standard chemotherapy as first-line treatment in small-cell lung cancer leads to a 27% risk reduction for death